Introduction to the Archimedes Model

Size: px
Start display at page:

Download "Introduction to the Archimedes Model"

Transcription

1 Introduction to the Archimedes Model Archimedes, Inc. Corporate Overview Healthcare Modeling Company Based in San Francisco Core technology Archimedes Model Mathematical of human physiology, diseases, interventions and healthcare systems Highly detailed Rigorously validated In development since 1993 David Eddy MD, PhD Len Schlessinger PhD Owned by Kaiser Permanente Spun out as independent organization 2006 Clients Include: American Cancer Society American Association American Heart Association Bristol Myers Squibb CDC Daiichi Sankyo Eli Lilly GlaxoSmithKline Humana Kaiser Permanente NCQA Robert Wood Johnson Foundation... a KAISER PERMANENTE Innovation 2 Publications The Basics The Relationship between Resistance and Related Metabolic Variables to Coronary Artery Disease: A Mathematical Analysis [» Care Publish Ahead of Print, 11/18/2008 ] The potential effects of HEDIS performance measures on the quality of care [»Health Affairs, 9/15/2008 ] The Impact of Prevention on Reducing the Burden of Cardiovascular Disease [»Circulation, 7/29/2008 ] Validation of Prediction of by Archimedes and Comparison with Other Predicting Models. [» Care, 5/28/2008 ] The Metabolic Syndrome and Cardiovascular Risk: Implications for Clinical Practice. [»International Journal of Obesity, 5/1/2008 ] Risk Calculator: A Simple Tool for Detecting Undiagnosed and Prediabetes. [» Care, 5/1/2008 ] Cure, Care, and Commitment: What Can We Look Forward To? [» Care, 4/15/2008 ] Reflections on science, judgment, and value in evidencebased decision making: a conversation with David Eddy [»Health Affairs, 6/19/2007 ] Medical Decision making: How it can, be improved [»Expert Voices, 5/15/2007 ] Linking Electronic Medical Records To Large Scale Simulation Models: Putting Rapid Learning On Turbo? [»Health Affairs, 1/26/2007 ] Accuracy versus transparency in Pharmacoeconomic ling: finding the right balance. [»Pharmacoeconomics, 6/6/2006 ] Bringing health economic ing to the 21st century. [»Value in Health, 5/30/2006 ] Clinical outcomes and cost effectiveness of strategies for managing people at high risk for diabetes. [»Annals of Internal Medicine, 8/16/2005 ] Earlier intervention in type 2 diabetes: The case for achieving early control. [»International Journal of Clinical Practice, 11/28/2005 ] Evidence based medicine: a unified approach. [»Health Affairs, 02/15/2005 ] Validation of the Archimedes diabetes. [» Care, 11/15/2003 ] Archimedes: a trial validated of diabetes. [» Care, 11/15/2003 ] Archimedes: a new for simulating health care systems: the mathematical formulation [Journal of Biomedical Informatics, 2/2002] The Archimedes Model is a mathematical of human physiology, diseases, interventions, and healthcare systems Physiology based Realistic i Rigorously validated Comprehensive Clinically and administratively detailed Enables decision makers to understand likely outcomes of various interventions 3 4 Physiology Based Family history Gliburide level Unexplained variance in T test Sex Race/ Age Type 1 Type 2 Amount Joint Efficiency of insulin use Glucose uptake by muscle Glucose by liver error and variation HbA1c Glucose test test HbA1c test diagnosis BMI Age, sex, race/ it Metformin Untreated insulin level Normal liver Care processes Fractional change in Urine ketone test Ketoacidosis To s Height Weight blood Diet and exercise HDL cholesterol LDL Triglyceride cholesterol s Smoking cardiac risk to blurred Hypoglycemia Blurred Patient takes action Memory Peripheral resistance Mean arterial Systolic blood Coronary artery stenosis to polyuria Polyuria Perception Cardiac output Arterial compliance Pulse \ to fatigue Fatigue To the To the To the Nephropathy To the CAD Retinopathy Neuropathy to thirst Thirst 5 6 1

2 Family history Sex Race/ Age BMI Height Type 1 Type 2 Age, sex, race/ Weight blood Peripheral resistance Cardiac output Gliburide level Unexplained variance in Joint (Pancreas) Glucose uptake by muscle efficiency (Muscle) Glucose by liver efficiency Untreated (Liver) insulin level Normal liver Metformin UKPDS data Diet and exercise HDL LDL Triglyceride Smoking cardiac risk cholesterol cholesterol s Mean Systolic Coronary arterial blood artery stenosis Arterial Pulse \ compliance To the To the To the To the Coronary Retinopathy Nephropath Neuropathy artery y disease error and variation Care processes Fractional change in to blurred to polyuria to fatigue to thirst T test diagnosis test test HbA1c test Urine ketone test Blurred Memory Polyuria Perception Fatigue Thirst To s Patient takes action Family history Sex Type 1 Race/ Type 2 Age Age, sex, BMI race/ Me tformin Height Weight Gliburide level Joint (Pancreas) Glucose uptake by muscle efficiency (Muscle) Glucose by li ver efficiency Untreated (Liver) insulin level Normal liver UKPDS data Diet and exercise blood HDL LDL Triglyceride Smoking cholesterol cholesterol s Mean Systolic Coronary Peripheral arterial blood artery resistance stenosis Cardiac Arterial Pulse \ output compliance To the To the To the Retinopathy Nephropa th Neuropathy y Unexplained variance in error and variation Care processes Fractional change in cardiac risk to blurred to polyuria to fatigue To the Coronary artery to thirst disease mo del Hypoglycemia Ketoacidosis T test diagnosis test te st HbA 1c test Urine ketone test To tre atment Ketoacidosis s Hypoglycemia Patient takes action Blurred Memory Polyuria Perception Fatigue Thirst 6/4/ Realistic Biological variables that are continuous in reality are continuous in the Model No discrete states or strata Time is continuous No intervals, steps, or annual jumps Any event can occur at any time Years, months, hours, minutes, seconds... Comprehensive Behaviors Symptoms Signs Diseases Outcomes 9 10 Sample Mapping to DRG Sample Mapping to DRG ID Event Type Event Description Time (days) 32 Visit CHF_Repeat--primaryCare 4, Procedure bloodpressure 4, Procedure ekg 4, Procedure fulllipidpanel 4, Procedure standardhistory 4, Procedure standardphysical 4, Encounter marking beginencounter 4, Health outcome Myocardial_Infarction 4, Admission emergencydepartmenttriage--chestpain 4, Admission emergencydepartment--myocardialinfarction 4, Procedure bloodpressure 4, Procedure chestpainhistory 4, Procedure chestpainphysical 4, Procedure chestxray 4, Procedure CPK_CPKMB 4, Procedure CPK_CPKMB 4, Procedure ekg 4, Health outcome Myocardial_Infarction_Diagnosed 4, Admission cardiaccatheterization--cardiaccatheterization 4, Procedure cardiaccatheterization 4, Procedure angioplasty 4, Procedure drugelutingstent 4, Admission CCU--myocardialInfarction 4, Procedure ekg 4, Admission telemetry--myocardialinfarction 4, Procedure ekg 4, Encounter marking endencounter 4, Health outcome RetinopathyThreeStepProgression 4,972 Begin encounter MI diagnosed Cardiac catheterization Angioplasty Drug eluting stent End encounter Steps in determining DRG: a) Locate inpatient encounters b) Search for key events which contribute to the DRG Diagnoses Procedures c) Use key events to determine the most appropriate DRG ID Event Type Event Description Time (days) 32 Visit CHF_Repeat--primaryCare 4, Procedure bloodpressure 4, Procedure ekg 4, Procedure fulllipidpanel 4, Procedure standardhistory 4, Procedure standardphysical 4, Encounter marking beginencounter 4, Health outcome Myocardial_Infarction 4, Admission emergencydepartmenttriage--chestpain 4, Admission emergencydepartment--myocardialinfarction 4, Procedure bloodpressure 4, Procedure chestpainhistory 4, Procedure chestpainphysical 4, Procedure chestxray 4, Procedure CPK_CPKMB 4, Procedure CPK_CPKMB 4, Procedure ekg 4, Health outcome Myocardial_Infarction_Diagnosed 4, Admission cardiaccatheterization--cardiaccatheterization 4, Procedure cardiaccatheterization 4, Procedure angioplasty 4, Procedure drugelutingstent 4, Admission CCU--myocardialInfarction 4, Procedure ekg 4, Admission telemetry--myocardialinfarction 4, Procedure ekg 4, Encounter marking endencounter 4, Health outcome RetinopathyThreeStepProgression 4,972 Begin encounter MI diagnosed Cardiac catheterization Angioplasty Drug eluting stent End encounter DRG 557: Percutaneous Cardiovascular Procedure with Drug-Eluting Stent with Major Cardiovascular Diagnosis 2007 Medicare base payment: $13,468 Medicare average length of stay: 4.1 days

3 Single integrated Enables analysis of Co morbidities Syndromes that affect multiple organ systems Multiple drugs Drugs with multiple effects Enables comparisons and priority setting across full spectrum of populations, diseases and interventions Is continually updated and validated Currently in the Model Coronary artery disease Stroke and complications Obesity Metabolic syndrome Hypertension Dyslipidemia Congestive heart failure Asthma Lung cancer Breast cancer Colon cancer Validation of the Model We Compare its Results to Real Results Validate the Model by simulating clinical trials and comparing results Select simulated population to match real population Simulated protocols match real protocols Follow up protocols match real ones Definitions of outcomes match real ones Use highest level of detail possible with trial description and People Treatments Same (Virtual) People Same (Virtual) Treatments ized Controlled Trials Real Outcomes Same? Virtual Outcomes Some Trials Against Which the Model has been Validated MRC HOPE DCCT 1º HOT SHEP MICRO HOPE DCCT 2º PPP HHS CARE 4 S CARDS LLRC LIPID IRMA Syst Eur WOSCOPS DPP Lewis ATO Z HPS UKPDS IDNT LIFE VA HIT ALL HAT ETDRS 14 LIFEdiab ANBP2 CAPRICORN MERIT HPS IDEAL TNT PROSPER SAVE Distinguishing Features of the Model Physiologically based Single integrated Co morbidities Combinations across populations, diseases and interventions Calculates the effects of interventions in physiologically realistic way Includes protocols and behaviors Includes the full range of outcomes Clinical Logistic and utilization (e.g. admissions) Financial Validated Flexible

4 Distinguishing Features of the Model Can tailor to specific populations, settings and costs Populations Demographics, behaviors, test results, symptoms, past medical histories, current conditions, current s All at individual level Protocols and practice patterns Guidelines Performance levels Costs Tests, s, visits, hospitalizations, procedures Distinguishing Features of the Model Can calculate effects of changes and new s New populations New science e.g. role of diet New tests or biomarkers New s New guidelines New goals New performance measures Changes in levels of performance or compliance Progress from year to year ISPOR 2009 Questions? Prioritization of Interventions in Metabolic Disease Pat McCollam, Pharm.D. Principal Research Scientist Global Health Outcomes Eli Lilly and Company Indianapolis, IN, USA... a KAISER PERMANENTE Innovation 21 Disclosure- Full Time Employee of Eli Lilly and Company Early Phase Drug Development Role of Global Health Outcomes Function Clinical Trials- economic and/or PRO measures within trials Work outside Clinical Trials to Examine- Burden of illness, epidemiology, cost of illness (including cost effectiveness), patterns regarding standard of care Early Phase Drug Development Therapeutic Areas may have multiple candidate molecules targeting similar clinical trial endpoints Examine novel methods to compare potential value of candidate molecules (clinical outcomes, cost effectiveness) Assess population characteristics for potential inclusion/exclusion criteria, event rates, size of clinical trial, drivers of economic costs, etc. 4

5 Early Phase Drug Development Prioritization Process- Fit in portfolio Expert opinion Published literature Probabilistic ing Others (incl Archimedes) Archimedes in the Literature Multiple examples of predicting clinical trial results Recent publications in diabetes and heart disease- Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for. Eddy DM, Schlessinger L, Kahn R. Arch Int Med 2005;143: Also contains an appendix describing differences between Archimedes and Markov The Impact of Prevention on Reducing the Burden of Cardiovascular Disease. Kahn R, Robertson RM, Smith R, Eddy D. Circulation 2008;118: Authors point out the ability to estimate burden of illness and examine multiple interventions in the same Archimedes in the Literature Objective: Evaluate 11 recommended prevention activities to reduce CVD morbidity, mortality, and costs in the US. Design & Methods: Data source- Person-specific specific data from NHANES IV (US), adults aged years Estimated number and characteristics for prevention candidates Archimedes created simulated population matched to the real US population (person by person) Simulate clinical trials (30 years duration) to examine each prevention activity alone or altogether Vary performance and compliance levels of the interventions Extensive sensitivity analyses Endpoints- health outcomes, quality of life, medical costs Circulation 2008;118: Archimedes in the Literature Note that many are primary prevention activities Circulation 2008;118: Archimedes in the Literature Results (1)- Approximately 78% of US adults were candidates for 1 or more interventions (wow!) Assuming maximum performance and full implementation of interventions over the 30 year period MI and stroke would decrease by 63% and 31%, respectively average life expectancy yg gain of 1.3 years possible for all adults Greatest benefits were seen for: ASA in high-risk, controlling pre- diabetes, weight reduction in obesity, BP reduction in diabetes, LDL reduction in CAD While many interventions had cost/qaly values <$50,000 (US), budget impact is not negligible given population sizes and long (30 years) period Provided guidance regarding capabilities Circulation 2008;118: Archimedes Model Was Next Step in Evaluating Potential Health Outcomes Novel method to compare potential value of candidate molecules Assess population characteristics for potential inclusion/exclusion criteria, event rates, clinical trial sample size, drivers of economic costs, etc. Attributes of Archimedes Trial-validated Incorporates disease progression and healthcare delivery Disease occurs in continuous fashion without the need for transition probabilities 5

6 New Molecule Development Unmet Medical Need Commercially Viable Probability Of Success Goal: Conduct a series of simulated clinical trials exploring multiple compounds with assumed effects on single or combinations of key biomarkers Design & Methods: Data source- NHANES IV adults age (US) Estimate number and characteristics for candidates Create simulated population matched to the real US population (person by person) Simulate clinical trials (10 years duration) to examine each intervention relative to standard of care (SOC) Multiple variables examined via sensitivity analyses Control arm to simulate full (100%) compliance with SOC, and separate control arm to simulate compliance levels of SOC seen in NHANES Each compound was also ed on a particular subpopulation p with high risk characteristics (metabolic syndrome, diabetes, or existing CVD) Endpoints- biomarker changes, outcomes, quality of life, direct medical costs, cost effectiveness Some information is proprietary and unable to be shared at this time Results (1)- Patient demographics and health characteristics at start MeS DM CVD Control 2 Subgroup Subgroup Subgroup Mean Age % of population Age > 65 yrs old Gender (% male) Total cholesterol (mg/dl) LDL cholesterol (mg/dl) HDL cholesterol (mg/dl) Triglycerides (mg/dl) Waist circumference (cm) BMI (kg/m^2) Systolic blood (mmhg) Diastolic blood (mmhg) Fasting (mg/dl) % Metabolic Syndrome % > 110 or diagnosed DM Number alive at baseline 47,850 14,671 4,218 1,591 Results (2)- Outcomes Example, Major Adverse Cardiac Events Results (3)- Outcomes Example, 1 st Myocardial Infarction in 6

7 Results (4)- Outcomes Example, 1 st MI in pre-existing existing CVD Results (5)- Outcomes Example, 1 st MI in Metabolic Syndrome Results (6)- Outcomes Example, Coronary Revascularization zard (%) Integrated Haz Results (7)- Outcomes Example, Estimate of 10 year MACE by High Risk Subgroup Control (n=48,000) MeS (n=14,700) (n=4,250) CVD (n=1,600) MI Stroke Note denominator change when moving to subgroups Next Steps- Explore cost effectiveness sensitivity analysis Web-based based tool to perform additional analyses for simulated population Limitations- US data. How can we understand OUS environment? How to estimate outcomes when a biomarker does not exist? How to efficacy and safety without large scale clinical data? Does one assume simple additive effects of new compound to SOC? Carefully specify initial cohort in order to maximize analyses Conclusions- Several interventions produced similar levels of outcome reduction by different mechanisms (biomarkers) of action Model allows examination of particular items of clinical (MACE) and economic (Revascularization) interest to estimate frequency and timing Powerful tool to examine potential trial outcomes if good inputs (biomarkers) are available 7

8 Thank You 8

Redesigning Health Care Delivery Systems

Redesigning Health Care Delivery Systems Redesigning Health Care Delivery Systems Transforming Care through Technology and Innovation Molly Porter, Director Kaiser Permanente International Copyright 2010 Kaiser Permanente August 2010 KP as a

More information

Archimedes, Medicare, and ARCHeS

Archimedes, Medicare, and ARCHeS Archimedes, Medicare, and ARCHeS David M Eddy MD PhD Archimedes, Inc www.archimedesmodel.com National Health Policy Forum Washington, DC June 8, 2007 Outline 1. The Archimedes Model Why we built it What

More information

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Know Your Number Aggregate Report Single Analysis Compared to National Averages Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics

More information

CARE PATHWAYS. Allyson Ashley

CARE PATHWAYS. Allyson Ashley CARE PATHWAYS Allyson Ashley WHAT IS A CARE PATHWAY? An explicit statement of the goals and key elements of care based on evidence, best practice, and patient s expectations and their characteristics The

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

APPENDIX F: CASE REPORT FORM

APPENDIX F: CASE REPORT FORM APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more

More information

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:

More information

Update on CVD and Microvascular Complications in T2D

Update on CVD and Microvascular Complications in T2D Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System

More information

DESCRIPTION OF THE ARCHIMEDES MODEL

DESCRIPTION OF THE ARCHIMEDES MODEL DESCRIPTION OF THE ARCHIMEDES MODEL ARCHeS Simulator 2.5 March 2013 David Eddy, MD, PhD Marc-david Cohen, PhD Table of Contents Table of Contents... 2 Introduction... 5 What s New in ARCHeS with Simulator

More information

How to Reduce CVD Complications in Diabetes?

How to Reduce CVD Complications in Diabetes? How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year

More information

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:

More information

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD

More information

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Presentation downloaded from http://ce.unthsc.edu Objectives Understand that the obesity epidemic is also affecting children and adolescents

More information

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

Blood Pressure Targets in Diabetes

Blood Pressure Targets in Diabetes Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet

More information

The Latest Generation of Clinical

The Latest Generation of Clinical The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular

More information

Measure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner

Measure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner 2011 EHR Measure Specifications The specifications listed in this document have been updated to reflect clinical practice guidelines and applicable health informatics standards that are the most current

More information

Using the Patient Activation Measure to Improve Outcomes and Control Costs

Using the Patient Activation Measure to Improve Outcomes and Control Costs Using the Patient Activation Measure to Improve Outcomes and Control Costs Judith H. Hibbard, DrPH Health Policy Research Group University of Oregon 2014 University of Oregon What is Activation? An activated

More information

DIABETES. A growing problem

DIABETES. A growing problem DIABETES A growing problem Countries still grappling with infectious diseases such as tuberculosis, HIV/AIDS and malaria now face a double burden of disease Major social and economic change has brought

More information

The clinical and economic benefits of better treatment of adult Medicaid beneficiaries with diabetes

The clinical and economic benefits of better treatment of adult Medicaid beneficiaries with diabetes The clinical and economic benefits of better treatment of adult Medicaid beneficiaries with diabetes September, 2017 White paper Life Sciences IHS Markit Introduction Diabetes is one of the most prevalent

More information

Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes

Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Authored by Clifford Bailey and James LaSalle on behalf of the Global Partnership for Effective Diabetes Management. The

More information

SCIENTIFIC STUDY REPORT

SCIENTIFIC STUDY REPORT PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established

More information

Achieving Quality and Value in Chronic Care Management

Achieving Quality and Value in Chronic Care Management The Burden of Chronic Disease One of the greatest burdens on the US healthcare system is the rapidly growing rate of chronic disease. These statistics illustrate the scope of the problem: Nearly half of

More information

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence

More information

Guidelines on cardiovascular risk assessment and management

Guidelines on cardiovascular risk assessment and management European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

Linking Electronic Medical Records To Large-Scale Simulation Models: Can We Put Rapid Learning On Turbo?

Linking Electronic Medical Records To Large-Scale Simulation Models: Can We Put Rapid Learning On Turbo? Archimedes Linking Electronic Medical Records To Large-Scale Simulation s: Can We Put Rapid Learning On Turbo? The Archimedes model offers one example of how mathematical modeling can assist in medical

More information

Prevention of Heart Disease: The New Guidelines

Prevention of Heart Disease: The New Guidelines Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015

More information

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the

More information

Standards of Medical Care in Diabetes 2016

Standards of Medical Care in Diabetes 2016 Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking

More information

The Metabolic Syndrome: Is It A Valid Concept? YES

The Metabolic Syndrome: Is It A Valid Concept? YES The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA

More information

The target blood pressure in patients with diabetes is <130 mm Hg

The target blood pressure in patients with diabetes is <130 mm Hg Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response

More information

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular

More information

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A

More information

Computer Modeling of Diabetes and Its Complications: A Report on the Fifth Mount Hood Challenge Meeting

Computer Modeling of Diabetes and Its Complications: A Report on the Fifth Mount Hood Challenge Meeting VALUE IN HEALTH 16 (2013) 670 685 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval Computer Modeling of Diabetes and Its Complications: A Report on the Fifth Mount

More information

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):

More information

Fasting or non fasting?

Fasting or non fasting? Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues

More information

Client Report Screening Program Results For: Missouri Western State University October 28, 2013

Client Report Screening Program Results For: Missouri Western State University October 28, 2013 Client Report For: Missouri Western State University October 28, 2013 Executive Summary PROGRAM OVERVIEW From 1/1/2013-9/30/2013, Missouri Western State University participants participated in a screening

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

County of Sacramento. Review of Population Health through Kaiser Permanente Data

County of Sacramento. Review of Population Health through Kaiser Permanente Data County of Sacramento Review of Population Health through Kaiser Permanente Data Dr. Diane Dailey, M.D., Chief of Business Health Engagement Eileen Peterson, MPH, RD, TPMG Business Health Consultant, Public

More information

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,

More information

RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES

RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES Risk Factors or Complications Glycemic Control Fasting & Capillary Plasma Glucose Anti-platelet

More information

CV Risk Management in Diabetes Mellitus

CV Risk Management in Diabetes Mellitus CV Risk Management in Diabetes Mellitus J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine University of California, San Francisco Mr. B 40 y/o Latino male c/o fatigue,

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

Exercise in Diabetes Mellitus. Pranisa Luengratsameerung,MD

Exercise in Diabetes Mellitus. Pranisa Luengratsameerung,MD Exercise in Diabetes Mellitus By Pranisa Luengratsameerung,MD What is the Diabetes Mellitus? action Insulin Defect release Abnormal glucose metabolism Symptoms Polyuria (frequent urination) Polyphasia

More information

What s New in Bariatric Surgery?

What s New in Bariatric Surgery? Bariatric Surgery: Update for the General Surgeon What s New in Bariatric Surgery? 2,000 B.C. 2,000 A.D. 1. America keeps getting fatter without an end in sight. 2. Bariatric surgery is not just about

More information

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

Changing the Course of Diabetes: Turning Hope into Reality

Changing the Course of Diabetes: Turning Hope into Reality Indian Health Service Special Diabetes Program for Indians 2014 Report to Congress Changing the Course of Diabetes: Turning Hope into Reality In response to the burgeoning diabetes epidemic among American

More information

Heart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial

Heart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial Heart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial Sripal Bangalore, MD, MHA, Chuan-Chuan Wun, PhD, David A DeMicco, PharmD,

More information

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Total risk management of Cardiovascular diseases Nobuhiro Yamada Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible

More information

Diabetes Mellitus Aeromedical Considerations. Aviation Medicine Seminar Bucharest, Romania. 11 th to 15 th November 2013

Diabetes Mellitus Aeromedical Considerations. Aviation Medicine Seminar Bucharest, Romania. 11 th to 15 th November 2013 Diabetes Mellitus Aeromedical Considerations Aviation Medicine Seminar Bucharest, Romania. 11 th to 15 th November 2013 Metabolic, Nutritional or Endocrine disorders Applicants with metabolic, nutritional

More information

Diabetes Mellitus: Implications of New Clinical Trials and New Medications

Diabetes Mellitus: Implications of New Clinical Trials and New Medications Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October

More information

Chronic Benefit Application Form Cardiovascular Disease and Diabetes

Chronic Benefit Application Form Cardiovascular Disease and Diabetes Chronic Benefit Application Form Cardiovascular Disease and Diabetes 19 West Street, Houghton, South Africa, 2198 Postnet Suite 411, Private Bag X1, Melrose Arch, 2076 Tel: +27 (11) 715 3000 Fax: +27 (11)

More information

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of

More information

2014/10/20. Management of Lipid Disorders Eric Klug Sunninghill, Sunward Park and CM JHB Academic Hospitals

2014/10/20. Management of Lipid Disorders Eric Klug Sunninghill, Sunward Park and CM JHB Academic Hospitals Management of Lipid Disorders Eric Klug Sunninghill, Sunward Park and CM JHB Academic Hospitals Sudden and unexpected deaths in an adult population, Cape Town, South Africa, 2001-2005 1 Sudden and unexpected

More information

Disclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.

Disclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures. Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California

More information

Practical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua

Practical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80

More information

American Academy of Insurance Medicine

American Academy of Insurance Medicine American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker

More information

The State of Play of Diabetes Indicators

The State of Play of Diabetes Indicators The State of Play of Diabetes Indicators South Australian and National Information Catherine Chittleborough Janet Grant Anne Taylor April 2003 Diabetes Clearing House Population Research and Outcome Studies

More information

Claudication Treatment Comparative Effectiveness: 6 Month Outcomes from the CLEVER Study

Claudication Treatment Comparative Effectiveness: 6 Month Outcomes from the CLEVER Study Claudication Treatment Comparative Effectiveness: 6 Month Outcomes from the CLEVER Study Authors: Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DC, Reynolds MR, Lewis BA, Cerezo J, Oldenburg

More information

Complications of Diabetes: Screening and Prevention

Complications of Diabetes: Screening and Prevention Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy

More information

Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age

Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age Craig A. Sponseller, Masaya Tanahashi, Hideki Suganami,

More information

Diabetes and the Heart

Diabetes and the Heart Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with

More information

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator

More information

Sponsor Novartis. Generic Drug Name Fluvastatin. Therapeutic Area of Trial Dyslipidemia

Sponsor Novartis. Generic Drug Name Fluvastatin. Therapeutic Area of Trial Dyslipidemia Page 1 Sponsor Novartis Generic Drug Name Fluvastatin Therapeutic Area of Trial Dyslipidemia Approved Indication Therapeutic area and approved indications in Germany: Hypercholesterolemia (HC), combined

More information

IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS

IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes

More information

The American Diabetes Association estimates

The American Diabetes Association estimates DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular

More information

Section 03: Pre Exercise Evaluations and Risk Factor Assessment

Section 03: Pre Exercise Evaluations and Risk Factor Assessment Section 03: Pre Exercise Evaluations and Risk Factor Assessment ACSM Guidelines: Chapter 3 Pre Exercise Evaluations ACSM Manual: Chapter 3 Risk Factor Assessments HPHE 4450 Dr. Cheatham Purpose The extent

More information

Fixed dose combination for Trusted Diabetes Control Lobna Farag Eltooy Head of Internal Medicine Department Assiut University

Fixed dose combination for Trusted Diabetes Control Lobna Farag Eltooy Head of Internal Medicine Department Assiut University Fixed dose combination for Trusted Diabetes Control By Lobna Farag Eltooy Head of Internal Medicine Department 1 Assiut University 3/18/2018 3/18/2018 3/18/2018 Diabetes Complications with Increasing HbA1c

More information

Adult Diabetes Clinician Guide NOVEMBER 2017

Adult Diabetes Clinician Guide NOVEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.

More information

Director, Employee Health & Productivity. Coordinator, Employee Health & Productivity

Director, Employee Health & Productivity. Coordinator, Employee Health & Productivity Director, Employee Health & Productivity Coordinator, Employee Health & Productivity Table 2:. ChartE: Female HDL Cholesterol Risk Levels Optimal Borderline High Risk 80% 60% 40% 20% 0% LDL Cholesterol

More information

Methods. Background and Objectives STRADIVARIUS

Methods. Background and Objectives STRADIVARIUS STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau

More information

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered

More information

Endocrinology TeleECHO Clinic Case Presentation Form

Endocrinology TeleECHO Clinic Case Presentation Form Endocrinology TeleECHO Clinic Case Presentation Form Complete ALL ITEMS on this form and fax to 503.228.4801 PLEASE NOTE that case consultations do not create or otherwise establish a provider-patient

More information

Treating Hypertension in 2018: What Makes the Most Sense Today?

Treating Hypertension in 2018: What Makes the Most Sense Today? Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or

More information

Lipid Management 2013 Statin Benefit Groups

Lipid Management 2013 Statin Benefit Groups Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date

More information

Environmental. Vascular / Tissue. Metabolics

Environmental. Vascular / Tissue. Metabolics Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood

More information

ACCORD, ADVANCE & VADT. Now what do I do in my practice?

ACCORD, ADVANCE & VADT. Now what do I do in my practice? ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com

More information

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein

More information

Diabetes Control and Complications in Public Hospitals in Malaysia

Diabetes Control and Complications in Public Hospitals in Malaysia ORIGINAL ARTICLE Diabetes Control and Complications in Public Hospitals in Malaysia Mafauzy M. FRCP For the Diabcare-Malaysia Study Group, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian,

More information

Type 2 Diabetes in Adolescents

Type 2 Diabetes in Adolescents Type 2 Diabetes in Adolescents Disclosures Paid consultant, Eli Lilly, Inc, Pediatric Type 2 Diabetes Clinical Trials Outline The burden of diabetes Treatment and Prevention Youth Diabetes Prevention Clinic

More information

Clinical and Economic Summary Report. for Employers

Clinical and Economic Summary Report. for Employers Clinical and Economic Summary Report for Employers Magaly Rodriguez de Bittner, PharmD, CDE, FAPhA Director, P 3 Program Dawn Shojai, PharmD Assistant Director, P 3 Program P 3 Clinical & Economic Summary

More information

TAHFA-South Texas HFMA Fall Symposium. Tuesday, October 17, from 10:45 AM 11:35 AM.

TAHFA-South Texas HFMA Fall Symposium. Tuesday, October 17, from 10:45 AM 11:35 AM. 1 TAHFA-South Texas HFMA Fall Symposium Tuesday, October 17, from 10:45 AM 11:35 AM. Dr. Anil T. Mangla, MS., PhD., MPH., FRSPH Director of Public Health and Associate Professor of Biomedical Science 2

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Metabolic Syndrome and Workplace Outcome

Metabolic Syndrome and Workplace Outcome Metabolic Syndrome and Workplace Outcome Maine Worksite Wellness Initiative June 15, 2010 Alyssa B. Schultz Dee W. Edington Current Definition* of Metabolic Syndrome At least 3 of the following: Waist

More information

HIHIM Clinical Cocepts for Managers 7/31/2009. Fernando Vega, MD 1

HIHIM Clinical Cocepts for Managers 7/31/2009. Fernando Vega, MD 1 Fernando Vega, MD HIHIM 409 July 31, 2008 Hyperglycemia characterized by relative or absolute lack of insulin secretion Varying degrees of insulin resistance Often associated with symptoms: polyruia, polydipsia,

More information